Abstract | AIM: METHODS: A total of 102 children with either acquired or congenital aplastic anemia aged 8.8±3.6 years (range 0.9-17.6 years) were included. Therapeutic drug monitoring (TDM) data for ciclosporin were collected. The population pharmacokinetic model of ciclosporin was described using the nonlinear mixed-effects modeling (NONMEM) VI software. The final model was validated using bootstrap and normalized prediction distribution errors. RESULTS: A one-compartment model with first-order absorption and elimination was developed. The estimated CL/F was 15.1, which was lower than those of children receiving stem cell or kidney transplant reported in the West (16.9-29.3). The weight normalized CL/F was 0.45 (range: 0.27-0.70) Lh(-1)·kg(-1). The covariate analysis identified body weight, serum creatinine and concomitant administration of the anabolic steroid stanozolol as individual factors influencing the CL/F of ciclosporin. CONCLUSION:
|
Authors | Shao-qing Ni, Wei Zhao, Jue Wang, Su Zeng, Shu-qing Chen, Evelyne Jacqz-Aigrain, Zheng-yan Zhao |
Journal | Acta pharmacologica Sinica
(Acta Pharmacol Sin)
Vol. 34
Issue 7
Pg. 969-75
(Jul 2013)
ISSN: 1745-7254 [Electronic] United States |
PMID | 23624757
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunosuppressive Agents
- Stanozolol
- Cyclosporine
|
Topics |
- Adolescent
- Anemia, Aplastic
(drug therapy, ethnology, physiopathology)
- Asian People
(ethnology)
- Body Weight
(drug effects, physiology)
- Child
- Child, Preschool
- Cyclosporine
(administration & dosage, pharmacokinetics)
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage, pharmacokinetics)
- Infant
- Kidney Function Tests
(methods)
- Male
- Metabolic Clearance Rate
(drug effects, physiology)
- Prospective Studies
- Stanozolol
(administration & dosage, pharmacokinetics)
|